Think it may just fade away as people move on because of price on inconsistency?
Hmm, I think this whole pellet thing has been a quality control failure. I also think it's likely that QC problems have been responsible for the delays thus far. These issues aren't necessarily the fault or negligence of a particular party. Completely legitimate pharmaceuticals suffer delays for the same reasons as have been discussed here: difficulty scaling up the synthesis, inconsistency between tablets, poor bio-availability of product due to poor choice of tablet fillers, etc.
With pharmaceuticals the final product is almost always of excellent quality for several reasons that do not apply to the "BF" market:
(1) Pharma companies are bound to strict quality standards by law; screw ups are incredibly costly -- just Google for
Johnson and Johnson recall if you want a good example.
(2) For novel products, Pharma companies usually posses patents and other legally defensible intellectual property ensuring their market exclusivity despite any delays.
(3) Pharma companies usually don't need to worry about sudden regulatory changes that outlaw the sale of their products; while delays reduce short-term revenues, they do not lead to a complete failure of the product and concomitant loss of investment.
(4) Pharma companies are likely to be better financed and more able to afford the measures needed to ensure quality.
In the BF market, (1) doesn't apply at all, and the concerns in (2) and (3) pressure vendors into releasing a product before it's ready. Essentially, the only motivation for releasing a quality product is the end-user experience. In the specific case of BF, a compromise was struck and the product was released despite unresolved QC issues. Users here bear witness.
What will happen is that the market will soon be flooded with pure active ingredient, having been properly identified (as 6-APB or not?) by another manufacturer. In all likelihood, the active was conclusively identified soon after the first samples were released, and the only reason we've not heard anything about it yet is because the manufacturer to be is intelligent enough to keep it under wraps until they've completely sorted out their scale-up and QC issues.
Trying to market this in the form of pellets was a bad move from a business standpoint and probably a harm reduction one as well. Perhaps the vendor(s) thought they could corner the market with the heavy branding and the pharmaceutical-like packaging. Whatever the motive, they were clearly ignorant to the complexities of the pharmaceutical business and in particular to the myriad of additional QC issues that can crop up with tableting. Now if they'd just sent the pure powder in those foil packs like they did with the later samples, it'd be quite a hit!
Hate to say this, but I think the vendors might have learned way more from this series of threads than anyone else, not that it will save the dumb ones in the end.
Alright, enough about vendors. Happy trips!
, just glued to this thread, been fun,
